20
Participants
Start Date
March 1, 2023
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2026
ARV-471
Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
Ribociclib
Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
Fondazione IRCCS San Gerardo dei Tintori, Monza
Hospital Universitario 12 de Octubre, Madrid
Moffitt Cancer Center - International Plaza, Tampa
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Moffitt Cancer Center, Tampa
Moffitt McKinley Hospital, Tampa
Hospital Universitario Virgen Del Rocio, Seville
Siteman Cancer Center - WUPI, Shiloh
Siteman Cancer Center - North County, Florissant
Siteman Cancer Center, St Louis
Barnes Jewish Hospital Department of Laboratories, St Louis
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine - Siteman Cancer Center, St Louis
Washington University School of Medicine, St Louis
Barnes Jewish Hospital Lab- South County, St Louis
Siteman Cancer Center - South County, St Louis
Siteman Cancer Center - West County, Creve Coeur
Siteman Cancer Center - St Peters, City of Saint Peters
UCSF Medical Center at Mission Bay, San Francisco
Stanford Women's Cancer Center, Palo Alto
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute - Chestnut Hill, Newton
BC Cancer Vancouver, Vancouver
BC Cancer Vancouver, Vancouver
The Ottawa Hospital - General Campus, Ottawa
Sunnybrook Research Institute, Toronto
CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi
Jewish General Hospital, Montreal
Lead Sponsor
Arvinas Estrogen Receptor, Inc.
INDUSTRY
Pfizer
INDUSTRY